FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949348766> ?p ?o ?g. }

• W2949348766 endingPage "270" @default.
• W2949348766 startingPage "270" @default.
• W2949348766 abstract "Background: While increasing use of proteasome inhibitors (PI) and immunomodulatory drugs (IMiDs) has improved treatment outcomes in multiple myeloma, traditional DNA-damaging agents are still employed in a subset of patients with refractory and/or aggressive disease to rapidly reduce disease burden. DT-PACE (dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide) and ESHAP (etoposide, prednisolone, cytarabine and cisplatin) are used to treat both primary refractory and relapsed disease, and by allowing the harvesting of peripheral blood stem cells, can serve as a bridge to autologous stem cell transplant (ASCT). The role for such approaches in an era with increasing use of new targeted biologically active agents is unclear. Aims: We aimed to define patient and disease features associated with improved outcomes that could guide future treatment decisions in real world practice. Methods: We identified a retrospective cohort of MM patients who received ESHAP or a DT-PACE containing regimen, treated between January 2010 and April 2018. Patient characteristics and outcomes were obtained from electronic patient records. Overall response rate (ORR) was assessed as per IMWG; progression free survival (PFS) and overall survival (OS) were analysed using Cox regression and Kaplan-Meier methods. Results: 54 patients were identified: median age 52 years (range 28–72), 35 (65%) male. 38 (70%) had primary refractory disease (Ref) at 6.6 months (1.1–34.0) from diagnosis; 16 (30%) patients had relapsed disease (Rel) at 15.7m (7.5–40.2) from diagnosis and 2.4m (0.1–27.1) from last therapy, after 2 (1–3) prior lines and 6 (38%) had had previous ASCT. 29/35 tested (83%) had high risk genetics, 21/29 (72%) patients were ISS 2/3, and 18 (33%) had extra-medullary disease. 48 (89%) had received a PI, 36 (67%) had received an IMiD, and 3 (6%) had received neither. 14/15 (93%) of ESHAP patients received 1 cycle and 27/38 (71%) of DT-PACE patients received 2 cycles, one patient received both. ORR was 53% for ESHAP with 27% CR/VGPR, and 76% for DT-PACE with 37% CR/VGPR; 14 (37%) Ref patients achieved CR/VGPR compared to 4 (25%) Rel patients, ORR was 71% and 63% respectively. 38 (70%) of all patients proceeded to ASCT. After a median follow-up of 37.6m: 30 (56%) patients had died, 11 (20%) were alive after progression and 13 (24%) were alive and progression-free. Median PFS was 7.5m (95%CI 4.6–10.4) and median OS was 16.0m (95%CI 0.6–31.4). There was strong evidence that patients who proceeded to ASCT had longer PFS (HR = 0.10, 95%CI 0.05–0.23, p = 0<0.001) and OS (HR = 0.20, 95%CI 0.09–0.41, p < 0.001) than patients who did not. Ref patients also fared better compared to Rel patients (PFS HR = 0.38, 95%CI 0.19–0.76, p = 0.01; OS HR = 0.46, 95%CI 0.22–0.95, p = 0.04). There was no strong evidence of a difference between ESHAP and DT-PACE patients (PFS HR = 1.21, 95%CI 0.83–1.76, p = 0.32; OS HR = 1.36, 95%CI 0.88–2.11, p = 0.16). In multivariable analyses, adjusting for other factors of interest, only the association with ASCT remained significant for PFS, as well as for OS (HR = 0.10, 95%CI 0.2–4.2, p < 0.01) alongside ISS disease stage (HR = 3.51, 95%CI 1.31–9.40, p = 0.01). Depth of response to ESHAP/DT-PACE was associated with PFS (p < 0.001) but not OS (p = 0.61).Summary/Conclusion: Our data confirm a role for infusional chemotherapy regimens in the management of poor risk MM, and suggest that patients who benefit most from these regimens are those with primary refractory disease and/or are able to receive ASCT as consolidation following salvage." @default.
• W2949348766 created "2019-06-27" @default.
• W2949348766 creator A5017190714 @default.
• W2949348766 creator A5027191169 @default.
• W2949348766 creator A5033041833 @default.
• W2949348766 creator A5048528508 @default.
• W2949348766 creator A5061550633 @default.
• W2949348766 creator A5068293508 @default.
• W2949348766 creator A5080334692 @default.
• W2949348766 creator A5082564837 @default.
• W2949348766 creator A5082858097 @default.
• W2949348766 date "2019-06-01" @default.
• W2949348766 modified "2023-10-18" @default.
• W2949348766 title "PF634 OUTCOMES OF SALVAGE WITH INFUSIONAL REGIMENS DT-PACE/ESHAP FOR REFRACTORY OR RELAPSED MULTIPLE MYELOMA (MM)" @default.
• W2949348766 doi "https://doi.org/10.1097/01.hs9.0000560820.01505.df" @default.
• W2949348766 hasPublicationYear "2019" @default.
• W2949348766 type Work @default.
• W2949348766 sameAs 2949348766 @default.
• W2949348766 citedByCount "0" @default.
• W2949348766 crossrefType "journal-article" @default.
• W2949348766 hasAuthorship W2949348766A5017190714 @default.
• W2949348766 hasAuthorship W2949348766A5027191169 @default.
• W2949348766 hasAuthorship W2949348766A5033041833 @default.
• W2949348766 hasAuthorship W2949348766A5048528508 @default.
• W2949348766 hasAuthorship W2949348766A5061550633 @default.
• W2949348766 hasAuthorship W2949348766A5068293508 @default.
• W2949348766 hasAuthorship W2949348766A5080334692 @default.
• W2949348766 hasAuthorship W2949348766A5082564837 @default.
• W2949348766 hasAuthorship W2949348766A5082858097 @default.
• W2949348766 hasBestOaLocation W29493487661 @default.
• W2949348766 hasConcept C126322002 @default.
• W2949348766 hasConcept C141071460 @default.
• W2949348766 hasConcept C143998085 @default.
• W2949348766 hasConcept C2776063141 @default.
• W2949348766 hasConcept C2776364478 @default.
• W2949348766 hasConcept C2776694085 @default.
• W2949348766 hasConcept C2777478702 @default.
• W2949348766 hasConcept C2778041864 @default.
• W2949348766 hasConcept C2778119113 @default.
• W2949348766 hasConcept C2780775027 @default.
• W2949348766 hasConcept C2781413609 @default.
• W2949348766 hasConcept C71924100 @default.
• W2949348766 hasConceptScore W2949348766C126322002 @default.
• W2949348766 hasConceptScore W2949348766C141071460 @default.
• W2949348766 hasConceptScore W2949348766C143998085 @default.
• W2949348766 hasConceptScore W2949348766C2776063141 @default.
• W2949348766 hasConceptScore W2949348766C2776364478 @default.
• W2949348766 hasConceptScore W2949348766C2776694085 @default.
• W2949348766 hasConceptScore W2949348766C2777478702 @default.
• W2949348766 hasConceptScore W2949348766C2778041864 @default.
• W2949348766 hasConceptScore W2949348766C2778119113 @default.
• W2949348766 hasConceptScore W2949348766C2780775027 @default.
• W2949348766 hasConceptScore W2949348766C2781413609 @default.
• W2949348766 hasConceptScore W2949348766C71924100 @default.
• W2949348766 hasIssue "S1" @default.
• W2949348766 hasLocation W29493487661 @default.
• W2949348766 hasLocation W29493487662 @default.
• W2949348766 hasOpenAccess W2949348766 @default.
• W2949348766 hasPrimaryLocation W29493487661 @default.
• W2949348766 hasRelatedWork W1967461244 @default.
• W2949348766 hasRelatedWork W2031089824 @default.
• W2949348766 hasRelatedWork W2033089666 @default.
• W2949348766 hasRelatedWork W2071038051 @default.
• W2949348766 hasRelatedWork W2162611585 @default.
• W2949348766 hasRelatedWork W2588234891 @default.
• W2949348766 hasRelatedWork W2751497063 @default.
• W2949348766 hasRelatedWork W3127479238 @default.
• W2949348766 hasRelatedWork W3134875278 @default.
• W2949348766 hasRelatedWork W2182322203 @default.
• W2949348766 hasVolume "3" @default.
• W2949348766 isParatext "false" @default.
• W2949348766 isRetracted "false" @default.
• W2949348766 magId "2949348766" @default.
• W2949348766 workType "article" @default.